Efficacy and Safety of Guihuang Formula in Treating Type III Prostatitis Patients with Dampness-Heat and Blood Stasis Syndrome: A Randomized Controlled Trial
Back to article page
|Updated:2022-04-22
|
Efficacy and Safety of Guihuang Formula in Treating Type III Prostatitis Patients with Dampness-Heat and Blood Stasis Syndrome: A Randomized Controlled Trial
Chinese Journal of Integrative MedicinePages: 1-6
Affiliations:
Author bio:
Funds:
Supported by the National Natural Science Foundation of China (No. 82104880), Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences (No. CI2021A02208) and the Nursery Project of Xiyuan Hospital of China Academy of Chinese Medical Sciences (No. 2019XYMP-23),Conflict of Interest,There is no conflict of interest.,Author Contributions,Gao QH and Guo J contributed to research implementation, experiment supervision, and fund managers. Liu SJ contributed to the writing of the paper and experimental design. Zeng Y and Zhao M contributed to the data analysis. Liu SJ, Deng YJ, ZY, Guo J, and Gao QH participated in the experiments.
Sheng-jing Liu, Ying-jun Deng, Yin Zeng, et al. Efficacy and Safety of Guihuang Formula in Treating Type III Prostatitis Patients with Dampness-Heat and Blood Stasis Syndrome: A Randomized Controlled Trial. [J/OL]. 1-6(0)
DOI:
Sheng-jing Liu, Ying-jun Deng, Yin Zeng, et al. Efficacy and Safety of Guihuang Formula in Treating Type III Prostatitis Patients with Dampness-Heat and Blood Stasis Syndrome: A Randomized Controlled Trial. [J/OL]. 1-6(0) DOI: 10.1007/s11655-022-3467-1.
Efficacy and Safety of Guihuang Formula in Treating Type III Prostatitis Patients with Dampness-Heat and Blood Stasis Syndrome: A Randomized Controlled Trial
Efficacy of Biejiajian Pill on Intestinal Microbiota in Patients with Hepatitis B Cirrhosis/Liver Fibrosis: A Randomized Double-Blind Controlled Trial
Reyanning Mixture on Asymptomatic or Mild SARS-CoV-2 Infection in Children and Adolescents: A Randomized Controlled Trial
Related Author
No data
Related Institution
Center of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China;Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China;National Center for Infectious Diseases, Beijing, China;Peking University Ditan Teaching Hospital, Beijing, China;Central of Integrated Chinese and Western Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China;China Traditional Chinese Medicine Holdings Co. Limited, Guangzhou, China
Department of Emergency, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China;Acupuncture and Massage College, Shanghai University of Traditional Chinese Medicine, Shanghai, China;Department of Health Management, The First Affiliated Hospital of Nanchang University, Nanchang, China;Jiangxi Provincial Traditional Chinese Medicine Nephropathy Clinical Research Center, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang, Jiangxi Province, China;Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China;Institute of Critical Care, Shanghai University of Traditional Chinese Medicine, Shanghai, China